Guardant Health Co-CEO sells 300,000 shares

Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported selling a total of 300,000 shares of Common Stock on 2025-09-09 in open market or private transactions at reported weighted-average prices of $59.4447 and $59.9346 per share.

Rhea-AI Filing Summary

Guardant Health Co-Chief Executive Officer Helmy Eltoukhy reported selling a total of 300,000 shares of Common Stock on 2025-09-09 in open market or private transactions at reported weighted-average prices of $59.4447 and $59.9346 per share. After these sales, he directly holds 2,123,499 shares of common stock. The reported prices reflect weighted-average figures for multiple trades within ranges from $58.79 to $59.78 and from $59.79 to $60.25 per share.

Insights

Corporate Governance Expert

TL;DR: A senior insider sold a material block of shares but retains a multi-million share holding; disclosure is clear and routine.

The reported open-market sales on a single date by the Co-CEO and director are material in the sense of being non-trivial share disposals disclosed under Section 16. The filing provides weighted-average prices and explanatory ranges, satisfying standard disclosure norms. Retention of over 2.1 million shares after the transactions indicates the insider remains a significant shareholder. The filing lacks any indication that sales were pursuant to a Rule 10b5-1 plan; the form does not check the plan box.

Securities Analyst

TL;DR: Two reported sales totaling 299,...shares at roughly $59.45–$59.93; transaction details are precise but convey no operational signal.

The Form 4 quantifies the exact share amounts and weighted-average prices and includes footnotes with price ranges for multiple trades. There are no derivative transactions or amendments disclosed. From a market-impact perspective, the disclosure is actionable for transparency but does not include context such as purpose of sale. The clear numeric detail supports accurate modeling of insider activity without requiring further inference.

Insider Trade Summary

Net Seller: 300,000 shares

Net Sell 2 txns

Insider Eltoukhy Helmy

Role Co-Chief Executive Officer

Sold 300,000 shs ($17.84M)

Type	Security	Shares	Price	Value
Sale	Common Stock	294,723	$59.4447	$17.52M
Sale	Common Stock	5,277	$59.9346	$316K

Holdings After Transaction: Common Stock — 2,123,499 shares (Direct)

Footnotes (2)

1. F1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.79 to $60.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold (total): 300,000 shares Shares sold at $59.4447: 294,723 shares Shares sold at $59.9346: 5,277 shares +1 more

4 metrics

Shares sold (total) 300,000 shares Aggregate common stock sold on 2025-09-09

Shares sold at $59.4447 294,723 shares Common stock sale reported with per-share price $59.4447

Shares sold at $59.9346 5,277 shares Common stock sale reported with per-share price $59.9346

Post-transaction holdings 2,123,499 shares Common stock held directly after reported transactions

Key Terms

weighted average price, open market or private transaction

2 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction market

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock sale did Guardant Health (GH) disclose?

Guardant Health reported that Co-CEO Helmy Eltoukhy sold 300,000 common shares. The transactions occurred on 2025-09-09 and were classified as open market or private sales, according to the Form 4 insider trading disclosure.

How many Guardant Health (GH) shares did Helmy Eltoukhy sell and at what prices?

Helmy Eltoukhy sold 294,723 shares at $59.4447 and 5,277 shares at $59.9346 per share. The reported prices are weighted averages for multiple trades executed within specified intraday price ranges.

How many Guardant Health (GH) shares does Helmy Eltoukhy still own after this sale?

After the reported sales, Helmy Eltoukhy directly holds 2,123,499 Guardant Health common shares. This post-transaction holding reflects his remaining direct ownership position as disclosed in the insider filing.

What transaction code was used in Guardant Health (GH)'s Form 4 filing?

The transactions were coded as “S,” indicating sales of common stock. The code description specifies that these were sales executed in open market or private transactions, consistent with standard SEC Form 4 transaction coding.

Were the Guardant Health (GH) insider sales executed in multiple trades?

Yes, the reported prices are weighted averages for multiple trades. Footnotes explain that the shares were sold in numerous transactions within price ranges of $58.79–$59.78 and $59.79–$60.25 per share, inclusive.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 07:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eltoukhy Helmy

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		S		294,723(1)	D	$59.4447	2,128,776	D
Common Stock	09/09/2025		S		5,277(2)	D	$59.9346	2,123,499	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.78 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.79 to $60.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Helmy Eltoukhy	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.